Cargando…

Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients

OBJECTIVES: This study aimed to explore factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer (aNSCLC) patients treated with immune checkpoint inhibitors (ICIs). METHODS: A total of 101 patients with aNSCLC receiving ICIs were included. The association bet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Yahua, Wu, Haishan, Lin, Mingqiang, Liu, Tianxiu, Li, Jiancheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605342/ https://www.ncbi.nlm.nih.gov/pubmed/34800914 http://dx.doi.org/10.1016/j.tranon.2021.101268

Ejemplares similares

Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma
por: Wu, Haishan, et al.
Publicado: (2021)

A Nutrition-Related Factor-Based Risk Stratification for Exploring the Clinical Benefits in the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Definitive Chemoradiotherapy: A Retrospective Cohort Study
por: Yu, Yilin, et al.
Publicado: (2022)

The novel pretreatment immune prognostic index discriminates survival outcomes in locally advanced non-operative esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: a 6-year retrospective study
por: Yu, Yilin, et al.
Publicado: (2022)

Neoadjuvant therapy for locally advanced non-small cell lung cancer: TKIs or immunotherapy?
por: Zhang, Zhenyang, et al.
Publicado: (2020)

Bioinformatics analysis combined with experiments predicts CENPK as a potential prognostic factor for lung adenocarcinoma
por: Ma, Jiayu, et al.
Publicado: (2021)

The identification of genes associated T-cell exhaustion and construction of prognostic signature to predict immunotherapy response in lung adenocarcinoma
por: Wu, Yahua, et al.
Publicado: (2023)

Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy
por: Wu, Yahua, et al.
Publicado: (2023)

Advanced Glycation End Products' Receptor DNA Methylation Associated with Immune Infiltration and Prognosis of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
por: Yang, Jun, et al.
Publicado: (2023)

A Novel Model Combining Tumor Length, Tumor Thickness, TNM_Stage, Nutritional Index, and Inflammatory Index Might Be Superior to the 8th TNM Staging Criteria in Predicting the Prognosis of Esophageal Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy
por: Chen, Xiaohui, et al.
Publicado: (2022)

A New Nomogram and Risk Stratification of Brain Metastasis by Clinical and Inflammatory Parameters in Stage III Small Cell Lung Cancer Without Prophylactic Cranial Irradiation
por: Qiu, Jianjian, et al.
Publicado: (2022)

Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xu, Yanjun, et al.
Publicado: (2021)

Change in Maximal Esophageal Wall Thickness Provides Prediction of Survival and Recurrence in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy and Surgery
por: Wu, Yahua, et al.
Publicado: (2021)

The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy
por: Ramagopalan, Sreeram, et al.
Publicado: (2021)

Immunotherapy in non-small cell lung cancer: advancements and challenges
por: Zhou, Fei, et al.
Publicado: (2021)

Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer
por: Shoji, Fumihiro, et al.
Publicado: (2022)

Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
por: Rocco, Danilo, et al.
Publicado: (2023)

Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer
por: Yang, Szu‐Chun, et al.
Publicado: (2023)

Analysis of Factors Affecting Brain Metastasis in Limited-Stage Small-Cell Lung Cancer Treated With Definitive Thoracic Irradiation
por: Wu, Shuting, et al.
Publicado: (2020)

Platinum versus immunotherapy for early resectable non-small cell lung cancer: A protocol for systematic review and meta analysis
por: Tong, Zhangwei, et al.
Publicado: (2020)

Association of heartbeat complexity with survival in advanced non-small cell lung cancer patients
por: Wu, Shuang, et al.
Publicado: (2023)

Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2018)

LAPS score for individualized treatment of advanced EGFR-mutated non-small cell lung cancer receiving EGFR-TKIs with or without bevacizumab
por: Wu, Yahua, et al.
Publicado: (2023)

Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review
por: Wang, Yimin, et al.
Publicado: (2022)

Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy
por: Xie, Dong, et al.
Publicado: (2022)

Potential role of immunotherapy in advanced non-small-cell lung cancer
por: de Mello, Ramon Andrade, et al.
Publicado: (2016)

Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report
por: Chen, Zhuxing, et al.
Publicado: (2021)

TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy
por: Zhao, Liqin, et al.
Publicado: (2020)

Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
por: Qiu, Bin, et al.
Publicado: (2021)

Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
por: Landi, Lorenza, et al.
Publicado: (2019)

Immunotherapy beyond progression in patients with advanced non-small cell lung cancer
por: Ge, Xiangwei, et al.
Publicado: (2020)

Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates
por: Suraya, Ratoe, et al.
Publicado: (2022)

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
por: Russano, Marco, et al.
Publicado: (2023)

Prognostic significance of platelet-to-albumin ratio in patients with esophageal squamous cell carcinoma receiving definitive radiotherapy
por: Huang, Zhiyu, et al.
Publicado: (2022)

Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Liu, Ying, et al.
Publicado: (2021)

Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer
por: Khozin, Sean, et al.
Publicado: (2019)

Non-Small-Cell Lung Cancer Immunotherapy and Sleep Characteristics: The Crossroad for Optimal Survival
por: Zarogoulidis, Paul, et al.
Publicado: (2023)

First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study
por: Wu, Yahua, et al.
Publicado: (2023)

Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase Inhibitors: Non-Responders versus Responders
por: Hsiao, Shih-Hsin, et al.
Publicado: (2013)

Bevacizumab loaded CalliSpheres® bronchial arterial chemoembolization combined with immunotherapy and targeted therapy for advanced lung adenocarcinoma
por: Liu, Haitao, et al.
Publicado: (2023)

Advances and challenges in immunotherapy of small cell lung cancer
por: Guo, Hanfei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u91jjrn8hd1lq6u98vtqupl15d